Effectiveness of Baricitinib in Alopecia Areata
March 2025
TLDR Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
This study evaluated the effectiveness of baricitinib in treating alopecia areata (AA) in a cohort of 39 patients, with a focus on achieving a Severity of Alopecia Tool (SALT) score of ≤20. At 36 weeks, 42.3% of patients reached this score, and at 52 weeks, 52.4% achieved it, indicating baricitinib's efficacy over a prolonged period. These results surpass those from previous clinical trials BRAVE-AA1 and BRAVE-AA2, where only 34% of patients reached a SALT ≤20 at week 36. The study also noted hypercholesterolemia as the most common adverse event. Despite the small sample size, the findings support baricitinib as an effective treatment option for AA.